Financials data is unavailable for this security.
View more
Year on year Sichuan Hebang Biotechnology Co Ltd 's revenues fell -32.33% from 13.04bn to 8.82bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 3.81bn to 1.28bn, a -66.29% decrease.
Gross margin | 16.20% |
---|---|
Net profit margin | 9.01% |
Operating margin | 11.04% |
Return on assets | 3.46% |
---|---|
Return on equity | 4.48% |
Return on investment | 4.33% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Sichuan Hebang Biotechnology Co Ltd fell by 1.64bn. However, the company earned 80.33m from its operations for a Cash Flow Margin of 0.91%. In addition the company used 782.23m on investing activities and also paid 943.60m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.15 |
---|---|
Tangible book value per share | 1.68 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.96 |
---|---|
Quick ratio | 1.14 |
Total debt/total equity | 0.2436 |
---|---|
Total debt/total capital | 0.1907 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -66.32%, respectively. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg) | 0.38% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | 18.85% |
EPS growth(5 years) | 29.10 |
---|---|
EPS (TTM) vs TTM 1 year ago | -51.42 |
More ▼